BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 7498464)

  • 1. The peripheral cannabinoid receptor: adenylate cyclase inhibition and G protein coupling.
    Bayewitch M; Avidor-Reiss T; Levy R; Barg J; Mechoulam R; Vogel Z
    FEBS Lett; 1995 Nov; 375(1-2):143-7. PubMed ID: 7498464
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activation of the human peripheral cannabinoid receptor results in inhibition of adenylyl cyclase.
    Slipetz DM; O'Neill GP; Favreau L; Dufresne C; Gallant M; Gareau Y; Guay D; Labelle M; Metters KM
    Mol Pharmacol; 1995 Aug; 48(2):352-61. PubMed ID: 7651369
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors.
    Felder CC; Joyce KE; Briley EM; Mansouri J; Mackie K; Blond O; Lai Y; Ma AL; Mitchell RL
    Mol Pharmacol; 1995 Sep; 48(3):443-50. PubMed ID: 7565624
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activation of mitogen-activated protein kinases by stimulation of the central cannabinoid receptor CB1.
    Bouaboula M; Poinot-Chazel C; Bourrié B; Canat X; Calandra B; Rinaldi-Carmona M; Le Fur G; Casellas P
    Biochem J; 1995 Dec; 312 ( Pt 2)(Pt 2):637-41. PubMed ID: 8526880
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Suppression of the humoral immune response by cannabinoids is partially mediated through inhibition of adenylate cyclase by a pertussis toxin-sensitive G-protein coupled mechanism.
    Kaminski NE; Koh WS; Yang KH; Lee M; Kessler FK
    Biochem Pharmacol; 1994 Nov; 48(10):1899-908. PubMed ID: 7986201
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anandamide, an endogenous cannabimimetic eicosanoid, binds to the cloned human cannabinoid receptor and stimulates receptor-mediated signal transduction.
    Felder CC; Briley EM; Axelrod J; Simpson JT; Mackie K; Devane WA
    Proc Natl Acad Sci U S A; 1993 Aug; 90(16):7656-60. PubMed ID: 8395053
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The CB1 cannabinoid receptor is coupled to the activation of protein kinase B/Akt.
    Gómez del Pulgar T; Velasco G; Guzmán M
    Biochem J; 2000 Apr; 347(Pt 2):369-73. PubMed ID: 10749665
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anandamide, a brain endogenous compound, interacts specifically with cannabinoid receptors and inhibits adenylate cyclase.
    Vogel Z; Barg J; Levy R; Saya D; Heldman E; Mechoulam R
    J Neurochem; 1993 Jul; 61(1):352-5. PubMed ID: 8515284
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A selective inverse agonist for central cannabinoid receptor inhibits mitogen-activated protein kinase activation stimulated by insulin or insulin-like growth factor 1. Evidence for a new model of receptor/ligand interactions.
    Bouaboula M; Perrachon S; Milligan L; Canat X; Rinaldi-Carmona M; Portier M; Barth F; Calandra B; Pecceu F; Lupker J; Maffrand JP; Le Fur G; Casellas P
    J Biol Chem; 1997 Aug; 272(35):22330-9. PubMed ID: 9268384
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Signaling pathway associated with stimulation of CB2 peripheral cannabinoid receptor. Involvement of both mitogen-activated protein kinase and induction of Krox-24 expression.
    Bouaboula M; Poinot-Chazel C; Marchand J; Canat X; Bourrié B; Rinaldi-Carmona M; Calandra B; Le Fur G; Casellas P
    Eur J Biochem; 1996 May; 237(3):704-11. PubMed ID: 8647116
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The endogenous cannabinoid anandamide is a lipid messenger activating cell growth via a cannabinoid receptor-independent pathway in hematopoietic cell lines.
    Derocq JM; Bouaboula M; Marchand J; Rinaldi-Carmona M; Ségui M; Casellas P
    FEBS Lett; 1998 Apr; 425(3):419-25. PubMed ID: 9563506
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of binding in a transfected cell line expressing a peripheral cannabinoid receptor (CB2): identification of cannabinoid receptor subtype selective ligands.
    Showalter VM; Compton DR; Martin BR; Abood ME
    J Pharmacol Exp Ther; 1996 Sep; 278(3):989-99. PubMed ID: 8819477
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CB1 receptor-G protein association. Subtype selectivity is determined by distinct intracellular domains.
    Mukhopadhyay S; Howlett AC
    Eur J Biochem; 2001 Feb; 268(3):499-505. PubMed ID: 11168387
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Voltage-dependent inhibition of Ca2+ channels in GH3 cells by cloned mu- and delta-opioid receptors.
    Piros ET; Prather PL; Law PY; Evans CJ; Hales TG
    Mol Pharmacol; 1996 Oct; 50(4):947-56. PubMed ID: 8863841
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of cannabinoid receptors in cultures of rat cerebellar granule cells.
    Pacheco MA; Ward SJ; Childers SR
    Brain Res; 1993 Feb; 603(1):102-10. PubMed ID: 8384043
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gi protein modulation induced by a selective inverse agonist for the peripheral cannabinoid receptor CB2: implication for intracellular signalization cross-regulation.
    Bouaboula M; Desnoyer N; Carayon P; Combes T; Casellas P
    Mol Pharmacol; 1999 Mar; 55(3):473-80. PubMed ID: 10051530
    [TBL] [Abstract][Full Text] [Related]  

  • 17. (-)-Delta9-tetrahydrocannabinol antagonizes the peripheral cannabinoid receptor-mediated inhibition of adenylyl cyclase.
    Bayewitch M; Rhee MH; Avidor-Reiss T; Breuer A; Mechoulam R; Vogel Z
    J Biol Chem; 1996 Apr; 271(17):9902-5. PubMed ID: 8626625
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cannabinoid receptors CB1 and CB2: a characterization of expression and adenylate cyclase modulation within the immune system.
    Schatz AR; Lee M; Condie RB; Pulaski JT; Kaminski NE
    Toxicol Appl Pharmacol; 1997 Feb; 142(2):278-87. PubMed ID: 9070350
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Concurrent stimulation of cannabinoid CB1 and dopamine D2 receptors augments cAMP accumulation in striatal neurons: evidence for a Gs linkage to the CB1 receptor.
    Glass M; Felder CC
    J Neurosci; 1997 Jul; 17(14):5327-33. PubMed ID: 9204917
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The endocannabinoid noladin ether acts as a full agonist at human CB2 cannabinoid receptors.
    Shoemaker JL; Joseph BK; Ruckle MB; Mayeux PR; Prather PL
    J Pharmacol Exp Ther; 2005 Aug; 314(2):868-75. PubMed ID: 15901805
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.